Onconova Therapeutics, Inc. ONTX shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and $4 price target. Onconova Therapeutics is a biopharmaceutical company focused on discovering and developing novel products to treat cancer.
Full Answer
Is ontx's stock trending up or down?
· 3 brokerages have issued 1 year price targets for Onconova Therapeutics' shares. Their forecasts range from $7.00 to $12.00. On average, they expect Onconova Therapeutics' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 825.9% from the stock's current price.
Should you buy Onconova (ontx) stock based on options?
· According to the company, it raised a total of $28.75 million from its public offering. That’s due to the company selling shares of ONTX stock in the offering at $1 each.
What does ontx's revenue and cash flow look like?
· The Onconova Therapeutics stock price fell by -5.11% on the last day (Friday, 6th May 2022) from $1.37 to $1.30. and has now fallen 3 days in a row.During the day the stock fluctuated 4.62% from a day low at $1.30 to a day high of $1.36.The price has fallen in 5 of the last 10 days and is down by -7.14% for this period. Volume has increased on the last day by 80 …
Will ontx outperform or underperform the S&P 500 over the long term?
Find the latest Onconova Therapeutics, Inc. (ONTX) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Stock up. Why Intra-Cellular ...
Is ONTX a good buy now?
Out of 2 analysts, 2 (100%) are recommending ONTX as a Strong Buy, 0 (0%) are recommending ONTX as a Buy, 0 (0%) are recommending ONTX as a Hold, 0 (0%) are recommending ONTX as a Sell, and 0 (0%) are recommending ONTX as a Strong Sell.
Will ONTX stock go up again?
Stock Price Forecast The 3 analysts offering 12-month price forecasts for Onconova Therapeutics Inc have a median target of 11.00, with a high estimate of 12.00 and a low estimate of 7.00. The median estimate represents a +708.82% increase from the last price of 1.36.
Is onconova a buy or sell?
Onconova Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Is ONTX going to reverse split?
Onconova Therapeutics, Inc. (ONTX) will effect a one-for-fifteen (1-15) reverse split of its common stock. The reverse stock split will become effective on Friday, May 21, 2021. In conjunction with the reverse split, the CUSIP number will change to 68232V801.
Is ORTX a good stock to buy?
Out of 4 analysts, 1 (25%) are recommending ORTX as a Strong Buy, 1 (25%) are recommending ORTX as a Buy, 1 (25%) are recommending ORTX as a Hold, 0 (0%) are recommending ORTX as a Sell, and 1 (25%) are recommending ORTX as a Strong Sell. What is ORTX's earnings growth forecast for 2022-2024?
What does onconova therapeutics do?
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
Why is onconova stock so low?
Onconova Therapeutics' stock price plummeted by more than 70% Monday morning after the company announced disappointing results from late-stage testing of its lead new drug candidate.
When did onconova go public?
July 25, 2013The shares are expected to begin trading on The NASDAQ Global Market on July 25, 2013 under the ticker symbol "ONTX."
Why did ONTX reverse split?
Instead, Onconova's stockholders who otherwise would have been entitled to a fraction of a share will receive a full share of common stock. The reverse stock split is intended primarily to increase the per share bid price of Onconova's common stock and satisfy the NASDAQ Capital Market continued listing requirement.
What happens in a reverse split shares?
During a reverse stock split, a company cancels its current outstanding stock and distributes new shares to its shareholders in proportion to the number of shares they owned before the reverse split.
What is a 1/15 reverse stock split?
The 1-for-15 reverse stock split will automatically convert 15 current shares of the Company's common stock into one share of common stock. No fractional shares will be issued in connection with the reverse stock split.
Is Onconova Therapeutics a buy right now?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are curren...
How has Onconova Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?
Onconova Therapeutics' stock was trading at $5.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World He...
Are investors shorting Onconova Therapeutics?
Onconova Therapeutics saw a decrease in short interest in the month of February. As of February 28th, there was short interest totaling 171,900 sha...
When is Onconova Therapeutics' next earnings date?
Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 16th 2022. View our earnings forecast for On...
How were Onconova Therapeutics' earnings last quarter?
Onconova Therapeutics, Inc. (NASDAQ:ONTX) posted its quarterly earnings data on Thursday, November, 11th. The biopharmaceutical company reported ($...
When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?
Onconova Therapeutics's stock reverse split on the morning of Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 202...
What price target have analysts set for ONTX?
3 Wall Street analysts have issued 12 month target prices for Onconova Therapeutics' shares. Their forecasts range from $7.00 to $12.00. On average...
Who are Onconova Therapeutics' key executives?
Onconova Therapeutics' management team includes the following people: Steven M. Fruchtman , President, Chief Executive Officer & Director ( Link...
Who are some of Onconova Therapeutics' key competitors?
Some companies that are related to Onconova Therapeutics include Annexon (ANNX) , scPharmaceuticals (SCPH) , BriaCell Therapeutics (BCTX) , Nex...
Signals & Forecast
Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development.
Support, Risk & Stop-loss
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
Is Onconova Therapeutics stock A Buy?
Onconova Therapeutics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Insiders are very positive buying more shares than they are selling in Onconova Therapeutics
In the last 100 trades there were 9.16 million shares bought and 1.43 million shares sold. The last trade was done 15 days ago by Gelder Mark S. Md who bough 17.5 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
About Onconova Therapeutics
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
What is Onconova Therapeutics?
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer.
When is Onconova 2021?
(NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Company’s management team will participate in A.G.P.’s Virtual Summer Healthcare Symposium on Thursday, June 17, 2021 . The event will consist of 1-on-1 virtual investor meetings. Investors participating in the virtual conference who are
Is Onconova a public company?
Here's the rundown: Onconova The Bucks County-based biopharmaceutical company raised $21 million in a public stock offering. Onconova (NASDAQ: ONTX) of Newtown sold 5 million shares of its common stock at $4.20 per share.
Is Onconova a multi-kinase inhibitor?
Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is planned to begin a dose-escalation and expansion Phase 1 trial in the U.S. in 2Q21, and a dose-escalation and expansion Phase 1 trial is currently underway in China. Onconova’s product candidate rigosertib is being studied in an investigator-initiated study program, ...
Is Onconova Therapeutics a public company?
NEWTOWN, Pa., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the closing of its previously announced underwritten public offering. A total of 5,000,000 shares of its common stock were sold at a public offering price of $4.20 per share. The gross proceeds of the offering to the Company are $21 million, before deducti
What is the quality of ONTX?
ONTX has a Quality Grade of D , ranking ahead of 8.68% of graded US stocks.
What is the strongest trending metric for ONTX?
ONTX's strongest trending metric is Value; it's been moving up over the last 45 weeks.
What is Onconova Therapeutics?
(NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that on June 17, 2021 it received a letter from The Nasdaq Stock Market LLC stating that the Company has regained compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550 (a) (2), as the Company’s common stock had a closing bid price of at least $1.00 per sha
How volatile is ONTX?
In terms of volatility of its share price, ONTX is more volatile than 99.17% of stocks we're observing.
Is Onconova a public company?
Here's the rundown: Onconova The Bucks County-based biopharmaceutical company raised $21 million in a public stock offering. Onconova (NASDAQ: ONTX) of Newtown sold 5 million shares of its common stock at $4.20 per share.
How much did Onconova raise?
Onconova announced after the market close on Tuesday that it raised $28.75 million via a stock offering.
How to tell if a stock is undervalued?
The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.
What are value stocks?
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.The following stocks are considered to be notable value stocks in the healthcare sector: 1. Onconova Therapeutics (NASDAQ: ONTX) - P/E: 0.85 2. Genesis Healthcare (NYSE: GEN) - P/E: 1.5 3. Coherus BioSciences (NASDAQ: CHRS) - P/E: 7.13 4. Seneca Biopharma (NASDAQ: SNCA) - P/E: 9.82 5. Five Star Senior Living (NASDAQ: FVE) - P/E: 3.65Onconova Therapeutics has reported Q2 earnings per share at -0.04, which has decreased by 33.33% compared to Q1, which was -0.03. Onconova Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Genesis Healthcare has reported Q2 earnings per share at -0.2, which has decreased by 171.43% compared to Q1, which was 0.28. Genesis Healthcare does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Coherus BioSciences has reported Q2 earnings per share at 0.81, which has increased by 68.75% compared to Q1, which was 0.48. Coherus BioSciences does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Seneca Biopharma has reported Q2 earnings per share at -0.15, which has increased by 37.5% compared to Q1, which was -0.24. Seneca Biopharma does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Five Star Senior Living reported earnings per share at 0.1, whereas in Q1 earnings per share sat at -0.55. Five Star Senior Living does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * 5 Value Stocks To Watch In The Real Estate Sector * 12 Energy Stocks Moving In Monday's Pre-Market Session (C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Why is endoxifen used?
More specifically, Endoxifen is used to minimize the risk of recurrence in patients after they’ve been treated for the initial onset. Breast cancer may not be the only cancer this leading candidate could wind up treating, though; Endoxifen could end up being used against ovarian cancer, too.
Is Atossa still in the exploratory stage?
Admittedly, Atossa is still in the exploratory stages of this application . Recently, under the Expanded Access Pathway program, the company obtained approval from the U.S. Food and Drug Administration (FDA) to test the drug on a single ovarian cancer patient. This could yield promising results, however.
Does Onconova Therapeutics have dividends?
Onconova Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Genesis Healthcare has reported Q2 earnings per share at -0.2, which has decreased by 171.43% compared to Q1, which was 0.28.
Onconova Therapeutics Inc ( ONTX ) Stock Market info
Recommendations: Buy or sell Onconova Therapeutics stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Onconova Therapeutics share forecasts, stock quote and buy / sell signals below.
Also on walletinvestor.com
Term Box: Best Onconova Therapeutics Inc forecast, ONTX stock price prediction, ONTX forecast, Onconova Therapeutics Inc finance tips, ONTX prediction, Onconova Therapeutics Inc analyst report, ONTX stock price predictions 2022, Onconova Therapeutics Inc stock forecast, ONTX forecast tomorrow, Onconova Therapeutics Inc technical analysis, ONTX stock future price, Onconova Therapeutics Inc projections, Onconova Therapeutics Inc market prognosis, ONTX expected stock price..